How to buy Blueprint Medicines Corporation stock | $107

Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines Corporation employs 420 staff and has a trailing 12-month revenue of around USD$811.2 million.

How to buy shares in Blueprint Medicines Corporation

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Blueprint Medicines Corporation. Find the stock by name or ticker symbol: BPMC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Blueprint Medicines Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$107, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Blueprint Medicines Corporation, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Blueprint Medicines Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Blueprint Medicines Corporation share price

Use our graph to track the performance of BPMC stocks over time.

Blueprint Medicines Corporation shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$107
52-week range	USD$43.29 - USD$125.61
50-day moving average	USD$107.7771
200-day moving average	USD$88.6737
Wall St. target price	USD$118.27
PE ratio	19.9094
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$6.178

Buy Blueprint Medicines Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Blueprint Medicines Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Blueprint Medicines Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Blueprint Medicines Corporation price performance over time

Historical closes compared with the close of $107 from 2021-01-11

1 week (2021-01-07)	0.15%
1 month (2020-12-15)	-9.60%
3 months (2020-10-15)	6.65%
6 months (2020-07-15)	33.58%

1 year (2020-01-15)	33.32%
2 years (2019-01-15)	61.75%
3 years (2018-01-13)	N/A
5 years (2016-01-15)	505.20%

Is Blueprint Medicines Corporation under- or over-valued?

Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Blueprint Medicines Corporation's P/E ratio

Blueprint Medicines Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Blueprint Medicines Corporation shares trade at around 20x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Blueprint Medicines Corporation's EBITDA

Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$331.8 million.

The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.

Blueprint Medicines Corporation financials

Revenue TTM	USD$811.2 million
Operating margin TTM	40.1%
Gross profit TTM	USD$-264,938,000
Return on assets TTM	17.71%
Return on equity TTM	36.29%
Profit margin	41.08%
Book value	$24.214
Market capitalisation	USD$6.9 billion

TTM: trailing 12 months

Shorting Blueprint Medicines Corporation shares

There are currently 3.1 million Blueprint Medicines Corporation shares held short by investors – that's known as Blueprint Medicines Corporation's "short interest". This figure is 4.9% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting Blueprint Medicines Corporation shares can be evaluated.

Blueprint Medicines Corporation's "short interest ratio" (SIR)

Blueprint Medicines Corporation's "short interest ratio" (SIR) is the quantity of Blueprint Medicines Corporation shares currently shorted divided by the average quantity of Blueprint Medicines Corporation shares traded daily (recently around 529349.31740614). Blueprint Medicines Corporation's SIR currently stands at 5.86. In other words for every 100,000 Blueprint Medicines Corporation shares traded daily on the market, roughly 5860 shares are currently held short.

However Blueprint Medicines Corporation's short interest can also be evaluated against the total number of Blueprint Medicines Corporation shares, or, against the total number of tradable Blueprint Medicines Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Blueprint Medicines Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Blueprint Medicines Corporation shares in existence, roughly 60 shares are currently held short) or 0.0648% of the tradable shares (for every 100,000 tradable Blueprint Medicines Corporation shares, roughly 65 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Blueprint Medicines Corporation.

Find out more about how you can short Blueprint Medicines Corporation stock.

Blueprint Medicines Corporation share dividends

We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.

Blueprint Medicines Corporation share price volatility

Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $43.29 up to $125.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.8861. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).

Blueprint Medicines Corporation overview

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Blueprint Medicines Corporation is owned by insiders or institutions?

  Currently 0.787% of Blueprint Medicines Corporation shares are held by insiders and 104.305% by institutions.

• How many people work for Blueprint Medicines Corporation?

  Latest data suggests 420 work at Blueprint Medicines Corporation.

• When does the fiscal year end for Blueprint Medicines Corporation?

  Blueprint Medicines Corporation's fiscal year ends in December.

• Where is Blueprint Medicines Corporation based?

  Blueprint Medicines Corporation's address is: 45 Sidney Street, Cambridge, MA, United States, 02139-4133

• What is Blueprint Medicines Corporation's ISIN number?

  Blueprint Medicines Corporation's international securities identification number is: US09627Y1091

• What is Blueprint Medicines Corporation's CUSIP number?

  Blueprint Medicines Corporation's Committee on Uniform Securities Identification Procedures number is: 09627Y109